EGFR and bone metastasis: Among patients who were diagnosed with stage IV NSCLC from 2003 to 2012 in our institute, 63.9% of patients with mutant EGFR were detected to have bone metastasis, while 54.4% of patients with wild type EGFR were found to have bone involvement (p = 0.004).